US-based clinical-stage cell therapy company AvenCell Therapeutics, Inc. confirmed on Thursday that the US Food and Drug Administration and the European Medicines Agency have cleared its Investigational New Drug application and approved its clinical trial application, respectively, for QUADvance (AVC-203-01), a phase I/II study for the treatment of relapsed/refractory B-cell malignancies.
AVC-203 is a CRISPR-engineered, allogeneic CAR-T therapy designed to target CD19 and/or CD20 receptors, which are present on nearly all B-cell malignancies.
The company plans to begin a Phase I/II study across multiple sites in the US and Europe to assess safety, tolerability, efficacy and pharmacokinetics in adults with relapsed or refractory B-cell cancers. A phase Ia dose escalation study is expected to be followed by a phase Ib dose expansion study and a Phase II pivotal trial.
AvenCell says this allogeneic, off-the-shelf approach could overcome scalability, consistency and cost challenges seen with traditional autologous CAR-T therapies.
European Commission approves Sobi's Aspaveli for rare kidney diseases
US FDA accepts IND application for AskBio's AB-1009
EspeRare and n-Lorem partner to expand European access to ASO therapies for rare genetic diseases
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
Kestra partners with Biobeat to add cuffless blood pressure monitoring to wearable defibrillator
argenx secures FDA priority review for VYVGART in seronegative myasthenia gravis
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Formosa Pharmaceuticals licenses APP13007 ophthalmic therapy to Samil for South Korea
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Sanofi's Teizeild approved in EU to delay stage 3 type 1 diabetes
Renalytix expands US clinical footprint with three kidneyintelX.dkd integrations
EQT Life Sciences exits Vivasure Medical in EUR185m sale to Haemonetics
FDA accepts NDA resubmission for Camurus' acromegaly drug Oclaiz